Zions Bancorporation N.A. Has $961,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

Zions Bancorporation N.A. raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 36.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 12,332 shares of the company’s stock after acquiring an additional 3,272 shares during the quarter. Zions Bancorporation N.A.’s holdings in AstraZeneca were worth $961,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. increased its stake in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. GHP Investment Advisors Inc. acquired a new position in AstraZeneca during the 2nd quarter worth approximately $26,000. Capital Performance Advisors LLP acquired a new position in AstraZeneca in the 3rd quarter valued at approximately $28,000. Pathway Financial Advisers LLC bought a new stake in shares of AstraZeneca in the 1st quarter valued at $29,000. Finally, Hobbs Group Advisors LLC bought a new position in AstraZeneca during the second quarter worth $35,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, TD Cowen increased their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $65.04 on Friday. The stock has a fifty day simple moving average of $75.79 and a 200-day simple moving average of $78.38. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The stock has a market cap of $201.66 billion, a PE ratio of 31.12, a P/E/G ratio of 1.21 and a beta of 0.47. The company has a current ratio of 0.93, a quick ratio of 0.69 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the business posted $0.87 EPS. The company’s revenue was up 18.0% on a year-over-year basis. Equities analysts anticipate that AstraZeneca PLC will post 4.07 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.